DelveInsight’s, “Postherpetic Neuralgia Pipeline Insight 2024” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Postherpetic Neuralgia pipeline landscape. It covers the Postherpetic Neuralgia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Postherpetic Neuralgia Pipeline. Dive into DelveInsight’s comprehensive report today! @ Postherpetic Neuralgia Pipeline Outlook
Key Takeaways from the Postherpetic Neuralgia Pipeline Report
- July 2024:- Merz Therapeutics GmbH- A Parallel-group Treatment, Proof-of-concept Phase 2, Multicenter, Double-blind, Randomized Two-arm Clinical Trial to Investigate the Efficacy and Safety of Subcutaneous NT 201 Injections Compared With Placebo Injections in Decreasing Pain Intensity in Male and Female Participants Aged 18 Years and Older With Moderate to Severe Chronic Peripheral Neuropathic Pain Due to Postherpetic Neuralgia or Peripheral Nerve Injury.
- June 2024:- iN Therapeutics Co. Ltd.- A Randomized, Double-blind, Placebo-controlled, Multiple-Ascending Dose Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Properties of iN1011-N17 After Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia Patients and to Assess the Relative Bioavailability of Mesylate vs Hydrochloride Salt Capsules in Healthy Volunteers.
- DelveInsight’s Postherpetic Neuralgia pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Postherpetic Neuralgia treatment.
- The leading Postherpetic Neuralgia Companies such as Haisco Pharmaceutical Group, Lexicon Pharmaceuticals, Shanghai SIMR Biotechnology Co., Ltd., Flexion Therapeutics, Medifron DBT, Oxford Cannabinoid Technologies, Acasti Pharma, Clexio Biosciences, Elorac Biotherapeutics, and others.
- Promising Postherpetic Neuralgia Therapies such as AJH-2947 100 mg (SAD), iN1011-N17 HCl Suspension (Part 1), and others.
Stay ahead with the most recent pipeline outlook for Postherpetic Neuralgia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Postherpetic Neuralgia Treatment Drugs
Postherpetic Neuralgia Emerging Drugs Profile
HSK16149: Haisco Pharmaceutical Group
HSK16149 is being developed by Haisco Pharmaceutical Group to treat Postherpetic Neuralgia. The company is currently conducting a multicenter, randomized, double-blind, placebo-controlled, 12-week, Phase III study to evaluate the efficacy and safety of HSK16149 capsules in chinease patients with Postherpetic Neuralgia.
LX9211: Lexicon Pharmaceuticals
LX9211 is an orally-delivered small molecule compound that we are developing as a treatment for neuropathic pain. Scientists identified the target of LX9211, adapter-associated kinase 1, or AAK1, in a target discovery efforts based on their discovery that mice lacking AAK1 exhibited increased resistance to induced neuropathic pain in preclinical models. LX9211 and another development candidate were discovered by scientists working within Lexicon’s drug discovery alliance with Bristol-Myers Squibb from which Lexicon hold exclusive development and commercialization rights. Currently, it is in Phase II stage of clinical trial evaluation to treat Postherpetic Neuralgia.
Explore groundbreaking therapies and clinical trials in the Postherpetic Neuralgia Pipeline. Access DelveInsight’s detailed report now! @ New Postherpetic Neuralgia Drugs
Postherpetic Neuralgia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
Postherpetic Neuralgia Products have been categorized under various Molecule types such as
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
Unveil the future of Postherpetic Neuralgia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Postherpetic Neuralgia Market Drivers and Barriers
Scope of the Postherpetic Neuralgia Pipeline Report
- Coverage- Global
- Postherpetic Neuralgia Companies- Haisco Pharmaceutical Group, Lexicon Pharmaceuticals, Shanghai SIMR Biotechnology Co., Ltd., Flexion Therapeutics, Medifron DBT, Oxford Cannabinoid Technologies, Acasti Pharma, Clexio Biosciences, Elorac Biotherapeutics, and others.
- Postherpetic Neuralgia Therapies- AJH-2947 100 mg (SAD), iN1011-N17 HCl Suspension (Part 1), and others.
- Postherpetic Neuralgia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Postherpetic Neuralgia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Postherpetic Neuralgia Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Postherpetic Neuralgia Companies, Key Products and Unmet Needs
Table of Content
- Introduction
- Executive Summary
- Postherpetic Neuralgia: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Postherpetic Neuralgia – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- HSK16149: Haisco Pharmaceutical Group
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- LX9211: Lexicon Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- AAT 730: Oxford Cannabinoid Technologies
- Drug profiles in the detailed report…..
- Inactive Products
- Postherpetic Neuralgia Key Companies
- Postherpetic Neuralgia Key Products
- Postherpetic Neuralgia- Unmet Needs
- Postherpetic Neuralgia- Market Drivers and Barriers
- Postherpetic Neuralgia- Future Perspectives and Conclusion
- Postherpetic Neuralgia Analyst Views
- Postherpetic Neuralgia Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: yash bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/